Percutaneous Renal Tumor Ablation

Background and indications

Percutaneous renal tumor ablation (cryoablation or radiofrequency/microwave) is a curative treatment for small renal cell carcinomas (T1a ≤ 4 cm). It is recommended as an alternative to partial nephrectomy in elderly patients, those with significant comorbidities, solitary kidney, renal insufficiency, bilateral renal tumors, or genetic predisposition syndromes (von Hippel-Lindau).

Cryoablation is the most used technique for renal tumors due to ice ball visualization allowing precise margin control.

Pre-procedure assessment

Assessment includes renal CT and/or MRI, staging workup (chest CT), blood panel (creatinine, GFR), percutaneous tumor biopsy (recommended before ablation to confirm histology), and urological tumor board discussion.

Procedure

Under general anesthesia and CT guidance, 1 to 4 cryoprobes are inserted into the tumor percutaneously via posterior or posterolateral approach. Two freeze-thaw cycles are performed with CT ice ball monitoring. The goal is a 5-10 mm margin around the tumor. For anterior tumors or those adjacent to organs (colon, ureter), hydrodissection (saline or CO2 injection) displaces at-risk structures. The procedure takes 1.5 to 3 hours.

Results and scientific evidence

For T1a renal tumors, cryoablation offers 90-95% local recurrence-free survival at 5 years, with superior renal function preservation compared to partial nephrectomy (Thompson et al., Urology, 2015; DOI: 10.1016/j.urology.2015.02.063). Cancer-specific survival is 95-98% at 5 years. Cryoablation is recommended by AUA and EAU guidelines as a treatment option for T1a tumors in selected patients.

Risks and complications

Local pain (20-30%), perirenal hemorrhage (5-10%, rarely requiring embolization), transient hematuria (5-10%), urinoma (< 1%, if collecting system injury). Major complication rate is 3-5%. Peri-procedural mortality is virtually nil.

Recovery

1 night hospitalization. Return to activities in 2-3 days. Control CT or MRI at 3, 6, 12 months then annual for 5 years.

Practical information

The procedure is performed as a short inpatient stay or outpatient depending on the case. It is performed by an interventional oncology radiologist, in coordination with the urologist.